A multicenter observational study to evaluate the efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in patients with unresectable neuroendocrine tumors (NEN).

A multicenter observational study to evaluate the efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in patients with unresectable neuroendocrine tumors (NEN). - A multicenter observational study to evaluate the efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in patients with unresectable neuroendocrine tumors (NEN).

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054127

Enrollment

200

Registered

2024-04-12

Start date

2024-04-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable neuroendocrine tumors (NEN)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible patients will include those who meet all of the following criteria and have received treatment at each institution between October 1, 2021, and December 31, 2023: Histologically diagnosed NEN based on resection or biopsy specimen. Unresectable or recurrent NEN. Initiation of PRRT with 177Lu-DOTATATE.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Objective response rate	—

Secondary

Measure	Time frame
Progression-free survival, overall survival, disease control rate, adverse event rate, response rate by primary site, disease control rate by primary site, improvement rate of endocrine symptoms in functional tumors	—

Countries

Japan

Contacts

Public ContactKohei Okamoto

National cancer center hospital Hepatobiliary and pancreatic oncology

kookamot@ncc.go.jp81-3-3542-2511

Outcome results